Product Center
Phase I/II Clinical Trial of the Re engineered Respiratory Syncytial Virus Vaccine (CHO Cells)(Adjuvant)Officially Launched
- Categories:Company news
- Author:
- Origin:
- Time of issue:2026-05-13
- Views:
(Summary description)On May 13, the launch meeting for the Phase I/II clinical trial of the recombinant respiratory syncytial virus vaccine (CHO cell-based) (adjuvant) independently developed by Ab&B Bio-Tech CO.,LTD.JS. (Ab&B Bio) was successfully held at the research site in Sichuan.
Phase I/II Clinical Trial of the Re engineered Respiratory Syncytial Virus Vaccine (CHO Cells)(Adjuvant)Officially Launched
(Summary description)On May 13, the launch meeting for the Phase I/II clinical trial of the recombinant respiratory syncytial virus vaccine (CHO cell-based) (adjuvant) independently developed by Ab&B Bio-Tech CO.,LTD.JS. (Ab&B Bio) was successfully held at the research site in Sichuan.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2026-05-13 14:26
- Views:
On May 13, the launch meeting for the Phase I/II clinical trial of the recombinant respiratory syncytial virus vaccine (CHO cell-based) (adjuvant) independently developed by Ab&B Bio-Tech CO.,LTD.JS. (Ab&B Bio) was successfully held at the research site in Sichuan. This marks the official entry of the company's first Class I new drug, which has received dual approvals from both Chinese and U.S. regulatory authorities, into a new phase of clinical development. It also represents another significant milestone in Ab&B Bio's steady fulfillment of its R&D pipeline commitments and continuous strengthening of its financial foundation.

Respiratory syncytial virus (RSV) is one of the primary pathogens causing respiratory infections in infants, children, and the elderly, leading to conditions such as pneumonia and bronchitis. The infection is most prevalent among children under 5 years of age and individuals aged 60 years and older. According to research statistics, a significant number of children and elderly individuals worldwide are hospitalized or even die annually due to RSV infection. However, there are currently no specific therapeutic agents for RSV disease, and management of acute infections primarily relies on supportive care. Vaccination has thus become the preferred clinical intervention for RSV prevention and control.
The recombinant respiratory syncytial virus (RSV) vaccine (CHO cell-based) (adjuvant) under investigation in this clinical trial employs big data analytics to enhance drug-like potential research, utilizing proprietary innovative technologies and a highly stable pre-F antigen sequence. Preclinical studies demonstrated that the vaccine not only stimulates the production of high-titer neutralizing antibodies against both RSV A2 and B strains but also induces robust cellular immune responses. In murine challenge protection studies, the vaccine reduced viral load in the lungs below the detection limit, exhibiting significant protective efficacy without evidence of vaccine-enhanced disease (VED), indicating high safety profiles. Additionally, the pre-F antigen structure exhibits exceptional thermal stability, eliminating the need for lyophilization and allowing long-term storage at 2–8°C in liquid form, thereby optimizing the manufacturing process for streamlined and efficient commercial production.
Relevant information
-
How to choose a reliable influenza vaccine during the flu season? An evidence-based guide for subunit vaccines for all age groups
Influenza (commonly referred to as the flu) is an acute respiratory infectious disease caused by the influenza virus. Unlike the common cold, influenza is highly contagious and is characterized primarily by systemic symptoms. Elderly individuals, children under the age of 5, patients with chronic diseases, pregnant women, and individuals with compromised immune systems are all considered high-risk populations for severe influenza [1]. A study based on national influenza surveillance and cause-of-death surveillance data revealed that, on average, there are 88,000 excess deaths related to influenza-associated respiratory diseases annually across China [2]. The total economic burden on outpatient patients with influenza ranges from RMB 801 to RMB 1,320, while the total economic burden on hospitalized influenza patients ranges from RMB 9,832 to RMB 23,833 [1]. In the face of the significant challenge posed by influenza, influenza vaccination is currently recognized worldwide as the most cost-effective and effective means of preventing influenza [1]. - The leap in influenza vaccine technology: from split-virus vaccines to whole-population subunit vaccines – what are the key advancements in the third-generation vaccines? 08-19
- Exclusive Release | The influenza subunit vaccine "HRK-X® 3" makes its nationwide debut, ushering in a new chapter of scientific protection for all populations! 08-15
- High-dose influenza vaccines now available across the entire population – marking a new phase in influenza prevention and control with subunit vaccines 08-15
- Deepening Strategic Synergy to Jointly Strengthen Public Health Defense: Chongqing Center for Disease Control and Prevention (Chongqing Institute of Preventive Medicine) visited Ab&B Bio for a visit and exchange session. 08-06
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us